NVX Holdings

NVX Holdings, operating through its subsidiary Nuvox Pharma, is a clinical-stage biotechnology company focused on developing a novel class of oxygen-therapeutic pharmaceuticals. The company's lead candidate, NVX-108, is a dodecafluoropentane (DDFP) emulsion designed to deliver oxygen to hypoxic tissues, which are common in conditions like ischemic stroke and solid tumors. By improving oxygenation, NVX-108 aims to enhance the efficacy of radiation therapy in cancer and reduce tissue damage in acute ischemic events. The company is currently advancing clinical trials in glioblastoma and stroke, leveraging its proprietary perfluorocarbon-based delivery platform. NVX Holdings is headquartered in Tucson, Arizona, and has received significant funding from the National Cancer Institute and the US Army.